Show Summary Details
Page of

Implantable cardioverter-defibrillators in heart failure 

Implantable cardioverter-defibrillators in heart failure
Implantable cardioverter-defibrillators in heart failure

Rachel C. Myles

and Derek T. Connelly

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 August 2018

The implantable cardioverter-defibrillator (ICD) is established asan effective therapy for ventricular arrhythmias and is now routinelyused for both primary and secondary prevention of suddencardiac death in at-risk populations. Patients with heart failure(HF) have an increased propensity to arrhythmic sudden deathand large randomized trials have demonstrated a clear mortalitybenefit following ICD implantation in selected HF patients. Despitethis, the optimal use of ICDs in patients with HF remains a particularlychallenging area of clinical practice. This is primarily becausepatients with HF are exposed to competing risks, which are both dynamic and difficult to quantify. As the cost and morbidity associatedwith ICD implantation are not insignificant, careful consideration of the risks and benefits associated with ICD implantationin each individual patient is required.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.